AI基金易方达产业机遇混合A（021179）披露2025年四季报，第四季度基金利润412.61万元，加权平均基金份额本期利润0.1396元。报告期内，基金净值增 长率为10.89%，截至四季度末，基金规模为4298.18万元。 该基金属于偏股混合型基金。截至1月22日，单位净值为1.612元。基金经理是杨宗昌，目前管理的2只基金近一年均为正收益。其中，截至1月22日，易方达 供给改革混合近一年复权单位净值增长率最高，达70.29%；易方达产业机遇混合A最低，为55.4%。 基金管理人在四季报中表示，四季度，本基金继续延续三季度以科技创新为配置主线，同时结合自下而上个股挖掘方式构建组合，结合三季度以来市场变化 对组合进行较大调整和再平衡，整体配置在风格上更趋均衡。考虑到存储模组公司、AI 产业链温控及电源公司涨幅较大，估值提升明显，我们大幅减持了 相关持仓。在 TMT 板块内，配置方向转向半导体设备与材料，重点布局受下游存储客户扩产影响较大的股票或者国产替代渗透率较低环节的公司。在周期 板块，我们提高了煤炭行业的配置比例，同时增配化工板块中部分调整较为充分、估值回归合理的个股。汽车板块，我们继续保持了相关公司的 ...

2026年开年，科创板迎来首例IPO终止案例。 1月14日，国内湿法清洗设备商亚电科技撤回上市申请，距离其2025年6月获受理仅过去半年。 这家拟募资9.5亿元的企业，最终未能跨越监管审核与市场竞争的双重门槛。 亚电科技的折戟并非个例，其暴露的客户依赖、现金流波动、业务结构失衡等问题，折射出国产半导体设 备企业在资本化道路上的共性困境。 | 极致的客户集中度风险 亚电科技的IPO之路，从一开始就布满暗礁。 最突出的风险当属极致的客户集中度：2025年上半年，公司光伏业务占主营收入51.85%，而这部分收入中 51.91%来自单一客户隆基绿能，形成"光伏业务依赖+单一客户依赖"的双重绑定。 根据证监会《监管规则适用指引——发行类第5号》，单一客户收入占比超50%即被认定为"重大依赖"，监 管层会重点核查业务持续性与稳定性。 尽管半导体行业存在客户集中的行业惯例，但亚电科技的依赖并非源于行业格局，而是自身市场拓展能力 不足——其前五大客户应收占比长期维持在80%-90%以上，远超盛美上海、至纯科技等同行的客户分散水 平。 | 现金流承压与行业周期风险 现金流的持续承压，成为压垮IPO的关键稻草。 亚电科技与光伏客 ...

Core Insights - The metal packaging coating materials industry is experiencing growth driven by stricter food safety regulations and a shift towards high-end products, with market size projected to increase from 171 billion yuan in 2020 to 222.6 billion yuan in 2024, and expected to reach 265.9 billion yuan by 2026 [1][13]. Industry Overview - Metal packaging coating materials are specialized functional coatings designed for metal packaging surfaces, providing protection against corrosion and chemical reactions, while meeting food contact and low VOC regulations [2][6]. - The industry is characterized by a clear division of labor within the supply chain, with upstream raw materials, midstream formulation and production, and downstream application in sectors like food and beverage, pharmaceuticals, and chemicals [7][9]. Market Dynamics - The market is witnessing a dual structure of stable demand in traditional sectors and expansion in emerging fields, with food and beverage being the core segment, accounting for 64% of the demand [9][10]. - The sales of two-piece and three-piece cans are projected to grow significantly, with two-piece can sales expected to rise from 45 billion units in 2020 to 70.73 billion units in 2024, and three-piece can sales from 39 billion to 61.2 billion units in the same period [10][11]. Regulatory Environment - Recent government policies have intensified scrutiny on food packaging materials, leading to the introduction of various standards that compel the industry to transition towards water-based and solvent-free high-end products [7][14]. Competitive Landscape - The industry exhibits a competitive landscape where foreign brands dominate the high-end market, while domestic companies are increasingly focusing on R&D to penetrate this segment [14][15]. - Key domestic players are making strides in developing water-based and powder coatings, aiming to break the monopoly of foreign companies in high-end markets [15]. Future Trends - The industry is expected to continue its shift towards environmentally friendly products, with a focus on water-based and solvent-free coatings becoming a core competitive advantage [16]. - Technological innovation will drive the development of multifunctional coatings, expanding into new application areas such as electric vehicle battery shells [16][17]. - The acceleration of domestic substitution will lead to a more concentrated and optimized industry structure, with increased collaboration across the supply chain [17].

Core Viewpoint - The article discusses the investment framework for the pharmaceutical industry ETF in 2026, emphasizing a dual-driven approach of demand and innovation to navigate the market recovery and differentiation after a prolonged bear market since 2021 [29]. Market Review - The CITIC Pharmaceutical Index decreased by 0.38%, outperforming the CSI 300 Index by 0.24 percentage points, ranking 25th among 30 primary industries [9]. - The top ten stocks by increase this week included ST Changyao, Hualan Biological Engineering, and Kangzhong Medical, with gains ranging from 6% to 70.38% [9]. - The bottom ten stocks by decrease included Kain Technology and Aidi Pharmaceutical, with declines of up to 45% [9]. Industry and Stock Events - The article highlights a shift in funding from active to passive management in the pharmaceutical sector, with passive funds becoming a significant part of the long-term funding structure [18]. - The article notes that the innovation drug sector is expected to see a transition from quantity to quality, focusing on differentiated products and internationalization by 2025 [12]. - The medical device sector is experiencing a recovery in bidding volumes, particularly in imaging equipment, and is benefiting from policies promoting home medical devices and accelerated overseas expansion [12]. - The article discusses the favorable conditions for the blood products industry, with relaxed approval for plasma stations and a clear growth path for the industry during the 14th Five-Year Plan period [13]. Investment Strategy - The article proposes a dynamic ETF configuration framework for the pharmaceutical sector, categorized into three layers: a core base of broad-based ETFs, a dual-driven layer focusing on innovative drugs and medical devices, and a defensive layer using traditional Chinese medicine and overseas biotech [22]. - The article emphasizes the importance of a systematic approach to ETF selection, considering liquidity, tracking quality, and cost [24]. - It suggests that the pharmaceutical sector is entering a new growth cycle driven by rigid demand and continuous innovation, necessitating a more structured and rhythmic ETF combination strategy [22].

以下文章来源于泽平宏观商学 ，作者泽平宏观商学 泽平宏观商学 . 前沿科技企业实战研学 读万卷书行万里路 014> 盲盒:头部智能驾驶企业 当前正处于从 L2 到 L4 自动驾驶迭代、从汽车向 通用机器人跨越的历史拐点。智驾芯片及解决方案市 场正以接近 50% 的年复合增长率奔向万亿规模。公司 凭借国产替代与技术普惠的双重红利，占据了中国智 驾市场的"半壁江山"。 在物理AI加速落地浪潮与国产替代加速的双重β 下,公司作为国产中大型算力芯片头部企业及具备软 硬一体能力的供应商，推动汽车从"功能"迈向"智 能"，让机器更懂人类，让出行更安全、更自由。 天工机器人:北京人形机器人创新中心 国家战略级平台,定义全栈自主新高度 北京人形机器人创新中心于2023年11月成立,是 国内首个省级人形机器人创新中心，也是国内首家具 身智能软硬件全栈科技公司,全面覆盖人形机器人大 脑、小脑、本体与数据的研发攻关并且构建了良好的 开源生态。 目前已推出自主研发的全国产化"具身天工"系 列人形机器人和"天轶"系列轮式人形机器人，可覆 盖工业制作、特种作业、物流分拣、商业导览等多元 场景,在人形机器人半马、运动会等多项行业竞赛中 以 ...

点击 最 下方 关注《材料汇》 ， 点击"❤"和" "并分享 添加 小编微信 ，寻 志同道合 的你 正文 材料汇文章标签汇总 如何下载（加入知识星球-材料汇） 材料汇部分文章 未来40年材料强国革命：这13大领域将重塑人类文明！ 国产替代爆发！14种卡脖子的先进封装材料，百亿赛道谁将突围？ | 先进封装材料 | 全球市场规模 | 中国市场规模 | 国外企业 | 国内企业 | | --- | --- | --- | --- | --- | | PSPI | | | 微系统、AZ电子材料 | 鼎龙股份、国风新材、三月科 | | | | 5.28亿美元(23年 7.12亿元(21 | Fujifilm, Toray, HD | 技、八亿时空、强力新材、瑞 | | | 全球) . 预计 | 年中国)、预 | | 华泰、诚志殷竹、艾森股份、 | | | 2028年将达到 | 汁到2025年增 | | 奥采德:波米科技、明士新材 | | | 20.32亿美元 | 长至9.67亿元 | 、旭化成 | 、东阳华芯、上海玟昕、理硕 | | | | | | 科技等 | | 光敏绝缘 | 2020年:0.1亿 | | | | | ...

Core Insights - The coronary access devices are essential consumables for percutaneous coronary intervention (PCI) surgeries, directly impacting surgical outcomes and complication control [1][6] - The industry is supported by a series of policies in China, including centralized procurement, innovation approvals, and grassroots medical construction, laying a solid foundation for high-quality development [6][10] - The number of coronary artery disease patients is steadily increasing globally and in China, with projections indicating 220 million patients worldwide and 27.879 million in China by 2024, highlighting significant growth potential for the industry [10] Industry Overview - Coronary access devices are specialized medical equipment and consumables used in PCI surgeries to establish and maintain access from the body surface to the coronary arteries, ensuring the smooth execution of angiography, balloon dilation, and stent implantation [1][6] - The devices are categorized into four main types: puncture devices, catheter systems, sheath sets, and auxiliary devices for pressure monitoring and vascular closure [3][4] Development Background - The development of coronary access devices is crucial for reducing cardiovascular disease mortality, enhancing medical accessibility, and promoting high-end device localization [6][8] - Recent policies in China aim to improve centralized procurement mechanisms, accelerate innovation device approvals, and standardize medical insurance payments, providing guidance for industry development [6][10] Market Analysis - The global coronary balloon dilatation catheter market is expanding, with functional balloons growing at a faster rate; the market size is expected to increase from $560 million in 2020 to $960 million in 2024, with a compound annual growth rate (CAGR) of 8.49% [12][14] - In China, the market is characterized by structural adjustments and rapid growth, with the general balloon market experiencing a temporary decline due to centralized procurement but expected to rebound, while functional balloons are projected to grow significantly, with a CAGR of 19.28% from 2024 to 2028 [14][16] Competitive Landscape - The competitive landscape of the coronary access device industry is tiered, with foreign companies dominating the high-end market while domestic leaders are accelerating their market penetration; by 2024, domestic companies are expected to capture 54.9% of the coronary balloon market [14][15] Future Trends - The industry is expected to evolve along three main directions: technological upgrades, deepening domestic substitution, and expansion of grassroots markets [16] - Innovations such as biodegradable materials and smart functions will drive high-end product iterations, while local companies will enhance core component localization through material and manufacturing process advancements [17][18] - The promotion of tiered diagnosis and treatment will reshape market demand, with a growing need for cost-effective and standardized products suitable for grassroots settings [18]

Core Viewpoint - Jiangsu Pizhou's semiconductor equipment company, Leuven Instruments, has completed the listing guidance filing with the Jiangsu Securities Regulatory Bureau and officially initiated its A-share IPO, indicating its entry into the capital market after over a decade in the semiconductor equipment sector [1]. Company Summary - Leuven Instruments was established in September 2015, with a registered capital of 196 million yuan. The company has a strong technical foundation and a diverse shareholding structure, including 19.82% held by the controlling shareholder Leuven Instruments and 2.98% by the Chinese Academy of Sciences Microelectronics Research Institute, which supports core technology development [2][3]. - The company specializes in providing equipment and process solutions for integrated circuit manufacturing, covering critical processes in various fields such as logic chips, memory, power devices, optics, and micro-displays. Its products include Ion Beam Shaping (IBS) and Ion Beam Deposition (IBD) equipment, which are at the forefront of the industry [3]. - Leuven Instruments holds 422 patents and has recently solved the uniformity issue of plasma concentration with its patented plasma etching machine, meeting the high-precision etching demands of 5G and artificial intelligence sectors. The company has also developed a magnetic storage etching machine that addresses the technical challenges of producing small-sized magnetic random access memory (MRAM), potentially breaking the monopoly of overseas manufacturers [3]. Industry Summary - Since 2025, 38 semiconductor companies have aimed for A-share listings, with a total fundraising target of nearly 100 billion yuan, covering key areas such as chip design, manufacturing, equipment, and materials. The semiconductor equipment sector is a focal point for domestic substitution and has attracted significant capital interest [4]. - The trend of domestic substitution and policy support presents a favorable development opportunity for equipment companies like Leuven Instruments that possess core technologies. The initiation of its IPO marks a significant milestone for the company and reflects the accelerated rise of the domestic semiconductor equipment industry [4].

Core Viewpoint - The article highlights the IPO initiation of Jiangsu Luwen Instruments, a semiconductor equipment company, indicating its significant growth and potential in the capital market, particularly in the context of the domestic semiconductor industry's development [1][4]. Group 1: Company Overview - Jiangsu Luwen Instruments, established in September 2015, has a registered capital of 196 million yuan and is led by Chairman Xu Kaidong [2][3]. - The company has a strong ownership structure, with 19.82% held by Leuven Instruments, providing international resources, and 2.98% by the Chinese Academy of Sciences, enhancing its core technology development [2][3]. - Luwen Instruments has secured 422 patents, including a recent one for a plasma etching machine that addresses uniformity issues, aligning with the high-precision etching demands of 5G and AI sectors [3]. Group 2: Market Position and Potential - The company specializes in providing equipment and process solutions for integrated circuit manufacturing, covering critical processes for various chip types, including logic chips and memory devices [3]. - Luwen Instruments has participated in 215 bidding processes, indicating high market recognition and acceptance [3]. - The semiconductor equipment sector is a key area for domestic substitution, with significant capital interest, as evidenced by 38 semiconductor companies aiming for A-share listings since 2025, targeting nearly 100 billion yuan in fundraising [4]. Group 3: Industry Context - The article emphasizes that the current trend of domestic substitution and policy support presents an optimal growth opportunity for companies like Luwen Instruments, which possess core technologies [4]. - The initiation of the IPO is seen as a crucial milestone for the company and a reflection of the accelerating rise of the domestic semiconductor equipment industry [4].

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2026 on February 10, 2026 [2][5] - The meeting will utilize the Shanghai Stock Exchange's online voting system, allowing shareholders to vote both on-site and online [3][4] - Shareholders must register to attend the meeting, with specific procedures outlined for both individual and corporate shareholders [11][14] Group 2 - The company forecasts its 2025 annual revenue to be between 430 million and 450 million yuan, representing a year-on-year increase of 42.04% to 48.65% [19][22] - The projected net profit for 2025 is expected to be between 110 million and 130 million yuan, reflecting a significant year-on-year growth of 135.30% to 178.09% [20][22] - The anticipated net profit attributable to the parent company is estimated to be between 90 million and 110 million yuan, indicating a year-on-year increase of 118.71% to 167.31% [20][22] Group 3 - The company plans to terminate the "Silicon Material Expansion Project for Integrated Circuit Etching Equipment" and will permanently supplement its working capital with the remaining raised funds of approximately 131.95 million yuan [39][44] - The decision to terminate the project is based on changes in the global market environment and the rapid development of domestic semiconductor manufacturers [44][46] - The company has effectively managed its project costs, resulting in surplus funds that will be redirected to support ongoing operations [47][48]